{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T02:20:27Z","timestamp":1784600427055,"version":"3.55.0"},"reference-count":39,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,6]]},"DOI":"10.1097\/jcp.0b013e31828f5a7a","type":"journal-article","created":{"date-parts":[[2013,4,20]],"date-time":"2013-04-20T14:15:49Z","timestamp":1366467349000},"page":"363-370","source":"Crossref","is-referenced-by-count":27,"title":["Tolerability, Pharmacokinetics, and Pharmacodynamics of Single-Dose Almorexant, an Orexin Receptor Antagonist, in Healthy Elderly Subjects"],"prefix":"10.1097","volume":"33","author":[{"given":"Petra","family":"Hoever","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Hay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mandana","family":"Rad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marzia","family":"Cavallaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joop M.","family":"van Gerven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasper","family":"Dingemanse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-13-20210128","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11065-011-9156-z","article-title":"Sleep and the brain.","volume":"21","author":"Colrain","year":"2011","journal-title":"Neuropsychol Rev"},{"key":"R2-13-20210128","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1159\/000236900","article-title":"Sleep disorders in the older adulta mini-review.","volume":"56","author":"Neikrug","year":"2010","journal-title":"Gerontology"},{"key":"R3-13-20210128","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S0022-3999(02)00435-X","article-title":"Sleep complaints cosegregate with illness in older adults: clinical research informed by and informing epidemiological studies of sleep.","volume":"53","author":"Vitiello","year":"2002","journal-title":"J Psychosom Res"},{"key":"R4-13-20210128","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1093\/sleep\/18.6.425","article-title":"Sleep complaints among elderly persons: an epidemiologic study of three communities.","volume":"18","author":"Foley","year":"1995","journal-title":"Sleep"},{"key":"R5-13-20210128","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1111\/j.1447-0594.2009.00537.x","article-title":"Late-life insomnia: a review.","volume":"9","author":"Fetveit","year":"2009","journal-title":"Geriatr Gerontol Int"},{"key":"R6-13-20210128","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/nrd2464","article-title":"Emerging anti-insomnia drugs: tackling sleeplessness and the quality of wake time.","volume":"7","author":"Wafford","year":"2008","journal-title":"Nat Rev Drug Discov"},{"key":"R7-13-20210128","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1517\/13543784.16.11.1785","article-title":"The hypocretinorexin receptor: therapeutic prospective in sleep disorders.","volume":"16","author":"Nishino","year":"2007","journal-title":"Expert Opin Investig Drugs"},{"key":"R8-13-20210128","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1073\/pnas.95.1.322","article-title":"The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity.","volume":"95","author":"de Lecea","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R9-13-20210128","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S0092-8674(00)80949-6","article-title":"Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior.","volume":"92","author":"Sakurai","year":"1998","journal-title":"Cell"},{"key":"R10-13-20210128","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/S0092-8674(00)81973-X","article-title":"Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation.","volume":"98","author":"Chemelli","year":"1999","journal-title":"Cell"},{"key":"R11-13-20210128","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/S0092-8674(00)81965-0","article-title":"The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene.","volume":"98","author":"Lin","year":"1999","journal-title":"Cell"},{"key":"R12-13-20210128","doi-asserted-by":"crossref","first-page":"4649","DOI":"10.1073\/pnas.0400590101","article-title":"Orexin peptides prevent cataplexy and improve wakefulness in an orexin neuron-ablated model of narcolepsy in mice.","volume":"101","author":"Mieda","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R13-13-20210128","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/S1474-4422(05)70196-4","article-title":"Hypocretins (orexins) and sleep-wake disorders.","volume":"4","author":"Baumann","year":"2005","journal-title":"Lancet Neurol"},{"key":"R14-13-20210128","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/79690","article-title":"A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains.","volume":"6","author":"Peyron","year":"2000","journal-title":"Nat Med"},{"key":"R15-13-20210128","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/S0006-3223(02)01740-7","article-title":"Diurnal variation of cerebrospinal fluid hypocretin-1 (Orexin-A) levels in control and depressed subjects.","volume":"54","author":"Salomon","year":"2003","journal-title":"Biol Psychiatry"},{"key":"R16-13-20210128","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1378\/chest.124.4.1381","article-title":"Plasma orexin-A levels in obstructive sleep apnea-hypopnea syndrome.","volume":"124","author":"Igarashi","year":"2003","journal-title":"Chest"},{"key":"R17-13-20210128","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.brainres.2005.04.064","article-title":"Selective stimulation of orexin receptor type 2 promotes wakefulness in freely behaving rats.","volume":"1048","author":"Akanmu","year":"2005","journal-title":"Brain Res"},{"key":"R18-13-20210128","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1038\/nm1544","article-title":"Promotion of sleep by targeting the orexin system in rats, dogs and humans.","volume":"13","author":"Brisbare-Roch","year":"2007","journal-title":"Nat Med"},{"key":"R20-13-20210128","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/clpt.2010.19","article-title":"Orexin receptor antagonism, a new sleep-promoting paradigm: an ascending single-dose study with almorexant.","volume":"87","author":"Hoever","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"R21-13-20210128","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1038\/clpt.2011.370","article-title":"Orexin receptor antagonism, a new sleep-enabling paradigm: a proof of concept clinical trial.","volume":"91","author":"Hoever","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"R22-13-20210128","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1046\/j.1365-2125.2003.02007.x","article-title":"Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications.","volume":"57","author":"Mangoni","year":"2004","journal-title":"Br J Clin Pharmacol"},{"key":"R23-13-20210128","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1146\/annurev.pharmtox.44.101802.121453","article-title":"Sex differences in pharmacokinetics and pharmacodynamics.","volume":"44","author":"Gandhi","year":"2004","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"R24-13-20210128","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/j.1365-2125.1974.tb00238.x","article-title":"Human performance after barbiturate (heptabarbitone).","volume":"1","author":"Borland","year":"1974","journal-title":"Br J Clin Pharmacol"},{"key":"R25-13-20210128","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/clpt.1991.122","article-title":"A study comparing the sensitivities of adaptive tracking, eye movement analysis and visual analogue lines to the effects of incremental doses of temazepam in healthy volunteers.","volume":"50","author":"Van Steveninck","year":"1991","journal-title":"Clin Pharmacol Ther"},{"key":"R26-13-20210128","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1177\/0269881108092595","article-title":"The pharmacokinetic and pharmacodynamic effects of SL65.1498, a GABA-A 2,3 selective agonist, in comparison with lorazepam in healthy volunteers.","volume":"23","author":"de Haas","year":"2009","journal-title":"J Psychopharmacol"},{"key":"R27-13-20210128","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/j.2044-8341.1974.tb02285.x","article-title":"The use of analogue scales in rating subjective feelings.","volume":"47","author":"Bond","year":"1974","journal-title":"Br J Med Psychol"},{"key":"R28-13-20210128","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1097\/00000542-199801000-00015","article-title":"Psychedelic effects of ketamine in healthy volunteers: relationship to steady-state plasma concentrations.","volume":"88","author":"Bowdle","year":"1998","journal-title":"Anesthesiology"},{"key":"R29-13-20210128","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1159\/000085205","article-title":"An E-health solution for automatic sleep classification according to Rechtschaffen and Kales: validation study of the Somnolyzer 24 7 utilizing the Siesta database.","volume":"51","author":"Anderer","year":"2005","journal-title":"Neuropsychobiology"},{"key":"R30-13-20210128","doi-asserted-by":"crossref","first-page":"109","DOI":"10.5664\/jcsm.26813","article-title":"Digital analysis and technical specifications.","volume":"3","author":"Penzel","year":"2007","journal-title":"J Clin Sleep Med"},{"key":"R31-13-20210128","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1093\/sleep\/30.11.1562","article-title":"Evaluation of automated and semi-automated scoring of polysomnographic recordings from a clinical trial using zolpidem in the treatment of insomnia.","volume":"30","author":"Svetnik","year":"2007","journal-title":"Sleep"},{"key":"R32-13-20210128","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1177\/009286159502900324","article-title":"Assessment of dose proportionality: report from the statisticians in the pharmaceutical industrypharmacokinetics UK joint working party.","volume":"29","author":"Gough","year":"1995","journal-title":"Drug Inf J"},{"key":"R34-13-20210128","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1517\/13543784.16.11.1785","article-title":"The hypocretinorexin receptor: therapeutic prospective in sleep disorders.","volume":"16","author":"Nishino","year":"2007","journal-title":"Expert Opin Investig Drugs"},{"key":"R35-13-20210128","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2165\/00003088-200544010-00002","article-title":"The influence of age and sex on the clearance of cytochrome P450 3A substrates.","volume":"44","author":"Cotreau","year":"2005","journal-title":"Clin Pharmacokinet"},{"key":"R36-13-20210128","first-page":"77","article-title":"Dose response effects of zolpidem in normal geriatric subjects.","volume":"52","author":"Scharf","year":"1991","journal-title":"J Clin Psychiatry"},{"key":"R37-13-20210128","doi-asserted-by":"crossref","first-page":"142","DOI":"10.2165\/00003088-199529030-00002","article-title":"Clinical pharmacokinetics and pharmacodynamics of zolpidem. Therapeutic implications.","volume":"29","author":"Salva","year":"1995","journal-title":"Clin Pharmacokinet"},{"key":"R38-13-20210128","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1177\/026988119901300102","article-title":"The sensitivity of pharmacodynamic tests for the central nervous system effects of drugs on the effects of sleep deprivation.","volume":"13","author":"van Steveninck","year":"1999","journal-title":"J Psychopharmacol"},{"key":"R39-13-20210128","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/sj.clpt.6100211","article-title":"Pharmacokinetic and pharmacodynamic interactions between zolpidem and caffeine.","volume":"821","author":"Cysneiros","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"R40-13-20210128","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1007\/BF02245054","article-title":"Sedative, memory, and performance effects of hypnotics.","volume":"116","author":"Roehrs","year":"1994","journal-title":"Psychopharmacology"},{"key":"R41-13-20210128","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/BF02246091","article-title":"Comparative pharmacodynamics of Ro 41-3696, a new hypnotic, and zolpidem after night-time administration to healthy subjects.","volume":"122","author":"Dingemanse","year":"1995","journal-title":"Psychopharmacology"}],"container-title":["Journal of Clinical Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/JCP.0b013e31828f5a7a","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T02:01:23Z","timestamp":1620957683000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00004714-201306000-00013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/jcp.0b013e31828f5a7a","relation":{},"ISSN":["0271-0749"],"issn-type":[{"value":"0271-0749","type":"print"}],"subject":[],"published":{"date-parts":[[2013,6]]}}}